Since the PPARγ is a key adipogenic regulator and the osteoblast and adipocyte, which are the two dominant pathways for BMSC to differentiate, have a reciprocal relationship (10-12), the PPARγ has been viewed as a prominent target for new anti-osteoporosis therapies that could increase bone formation or prevent bone loss. The gene discussed is PPARG; the disease is osteoporosis.